Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals for the deal to go through. The approval by the Federal Trade Commission (FTC) means that Pfizer has met its target of ...
And then, second one, just on Seagen, just wondering how the integration is coming along and if you have any updates to some of the metrics that you gave like sales in 2030 and what have you for the Seagen deal? Albert Bourla--Chairman and Chief Executive Officer OK. Dave, let's star...
Pfizer has also repeatedly said that the Seagen deal brings a proven antibody-drug conjugate platform that enhances its commercial structure and could help the company become a"world-class oncology leader." Pfizer has said Seagen could contribute more than$10 billion in risk-adjusted salesby 2030 ...
Pfizer (PFE) got over $85B orders Tuesday in an investment-grade jumbo bond sale, one of the biggest in history, to fund its Seagen (SGEN) acquisition. Read more here.
Pfizer also said last year it plans to add $25 billion in revenue through deal-making by 2030. In March, the company took a big step toward that goal with the $43 billion acquisition of Seagen, which it said could contribute more than$10 billionin risk-adjusted sales by 2030 with its ...
Finally, we closed the Seagen acquisition. In the current regulatory environment, being able to close such a large acquisition demonstrates our ability to successfully engage with regulatory bodies. Our deliberate and strategic efforts throughout 2023 created a strong foundation to support us. We are...
Gene therapy Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku January 14, 2025 · 2 min read · Tristan Manalac Cancer Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo January 14, 2025 ...
It has also tried rebuilding its pipeline with acquisitions, including the takeovers of Seagen, Arena Pharmaceuticals and Global Blood Therapeutics. But a piece of the $5.4 billion deal unraveled after Pfizer pulled its sickle cell drug, Oxbryta, from the market following patient deaths. So, is ...
MORE ON THIS TOPIC Multiple sclerosis FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs January 23, 2025 · 2 min read · Tristan Manalac Manufacturing Samsung Biologics Continues Mega-Deal Streak With $1.4B European Contract
divan said. cancer drugs padcev and adcetris, which the company acquired through its $43 billion buyout of seagen last year, are of particular interest to investors. william couchman, an executive at investment firm birmingham capital management, said he expects better results fro...